Ketamine for postoperative avoidance of depressive symptoms: the K-PASS feasibility randomised trial
Authors' conclusion
Patient recruitment, medication administration, and clinical outcome measurement appear to be highly feasible, with blinding maintained.
Study context
- Population
- Adults with depression scheduled for inpatient surgeryallocated a treatment
- Participants
- 32 adults
- Comparison
- Postoperative ketamine infusion vs normal saline placebo
- Ketaminen = 16
- Placebon = 16reference
- Primary endpoint
- Feasibility: fraction of approached patients randomised, fraction of randomised patients completing the study infusion, fraction of scheduled depression assessments completed
Methodological detailsfeasibility, single-centre, triple-blind, placebo-controlled
- Feasibility
- Single-centre
- Triple-blind
- Placebo-controlled
Primary result
As reported in the abstract
Feasibility
Approached patients randomised after protocol change (1.5 patients per week)
31 of 101
31%
Study infusion completed without interruption
30 of 32
94%
Scheduled depression assessments completed
170 of 192
89%
Further findings
| Outcome | Difference-in-differences (point) (95% CI) | |
|---|---|---|
| Depressive symptoms (Montgomery-Asberg Depression Rating Scale), change from baseline · post-infusion day 4Pre-specified time point of interest | −1.00 (−3.23 to 1.73) | |
| −4−202Difference, point (linear scale) |
| Outcome | Ketamine | Placebo |
|---|---|---|
| Blinding: correct guess of intervention received · post-infusion day 1 | 7/16 | 7/16 |
Depressive symptoms (Montgomery-Asberg Depression Rating Scale), change from baseline · post-infusion day 4
- Median depressive symptoms decreased in both groups; between-group difference did not persist at other time points
Original publication
Ketamine for postoperative avoidance of depressive symptoms: the K-PASS feasibility randomised trial. BJA Open. Published 15 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →